Some 50 experts and executives in the biopharma sector shared their views on the major trends they expect to see driving change in the clinical trials arena in 2024. Artificial intelligence applied to clinical development, greater use of remote monitoring and increased patient diversity in trials were key themes.
The executives we surveyed on the clinical trial landscape identified several sweeping trends that are expected to drive change over the coming year. As in so many spheres, data, digital technology and artificial intelligence (AI) are at the heart of much of this change.
Human Challenge Trials
“Amid greater interest in infectious and respiratory disease, human challenge trials (HCTs) are being increasingly used by global biopharma,” pointed out Yamin ‘Mo’ Khan, CEO of hVIVO Plc, an AIM-listed CRO. “We saw active HCTs growing by 44% CAGR [compound annual growth rate] between 2020-2023. We expect to see this growth to continue, as the early efficacy data from a HCT can de-risk clinical assets and accelerate the speed to market for key antivirals and vaccines via Breakthrough or Fast Track designations.”
hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.
